Glenmark Life Sciences Ltd.

NSE: GLS BSE: 543322 SECTOR: Pharmaceuticals & Drugs  89k   664   187

380.00
+3.45 (0.92%)
NSE: 07 Oct 03:56 PM

Price Summary

Today's High

₹ 384.1

Today's Low

₹ 376.2

52 Week High

₹ 676.4

52 Week Low

₹ 370

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4656.03 Cr.

Enterprise Value

4143.87 Cr.

No. of Shares

12.25 Cr.

P/E

10.92

P/B

2.16

Face Value

₹ 2

Div. Yield

5.53 %

Book Value (TTM)

₹  176.25

CASH

512.16 Cr.

DEBT

0 Cr.

Promoter Holding

82.85 %

EPS (TTM)

₹  34.81

Sales Growth

12.63%

ROE

29.87 %

ROCE

42.24%

Profit Growth

19.1 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.63%
3 Year33.8%
5 YearNA

Profit Growth

1 Year19.1%
3 Year28.88%
5 YearNA

ROE%

1 Year29.87%
3 Year72.87%
5 Year133.94%

ROCE %

1 Year42.24%
3 Year108.2%
5 Year170.47%

Debt/Equity

0

Price to Cash Flow

7.79

Interest Cover Ratio

21.2033116372219

CFO/PAT (5 Yr. Avg.)

0.931184354911498

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 82.85 0
Mar 2022 82.85 0
Dec 2021 82.85 0
Sep 2021 82.84 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 28.8819966265189% for the Past 3 years.
  • The company has shown a good revenue growth of 33.7981103233021% for the Past 3 years.
  • Company has been maintaining healthy ROE of 72.8743755472582% over the past 3 years.
  • Company has been maintaining healthy ROCE of 108.197762863189% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 21.2033116372219.
  • The Company has been maintaining an effective average operating margins of 22.7122614530264% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 2.84866671487222.
  • The company has a high promoter holding of 82.85%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 524.9 561.76 522.5 514.06 489.87
Total Expenditure 364.45 394.42 376.44 371.85 343.1
Operating Profit 160.45 167.34 146.06 142.21 146.77
Other Income 3.99 2.09 3.53 5.1 9.49
Interest 20.55 7.23 0.06 0.13 0.14
Depreciation 8.92 9.67 9.74 9.55 9.88
Exceptional Items 0 0 0 0 0
Profit Before Tax 134.97 152.54 139.8 137.63 146.25
Tax 34.05 37.33 36.09 38.73 37.51
Profit After Tax 100.91 115.2 103.71 98.9 108.73
Adjusted EPS (Rs) 9.36 9.4 8.46 8.07 8.87

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 0.25 886.42 1537.31 1885.17 2123.21
Total Expenditure 0.26 639.25 1065.35 1294.09 1507.15
Operating Profit -0.01 247.18 471.96 591.07 616.06
Other Income 0 0.99 11.99 0.81 14.7
Interest 0 0.61 33.52 87.55 27.96
Depreciation 0 19.26 29.37 33.39 37.88
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.01 228.3 421.07 470.94 564.93
Tax 0.42 32.71 107.97 119.36 146.2
Net Profit -0.43 195.59 313.1 351.58 418.72
Adjusted EPS (Rs.) -7.89 18.14 29.04 32.61 34.17

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 0.01 1.96 1.96 1.96 24.51
Total Reserves -1.41 86.17 399.73 750.79 2029.81
Borrowings 0 0 0 0 0
Other N/C liabilities 0 6.86 16.45 22.89 32.7
Current liabilities 1.48 1380.41 1307.46 1444.93 746.8
Total Liabilities 0.09 1475.4 1725.6 2220.57 2833.81
Assets
Net Block 0 456.31 546.25 572.8 595.03
Capital WIP 0 80.33 10.73 14.1 91.69
Intangible WIP 0 0.07 0 0 0
Investments 0 0.08 0.08 0.08 0.08
Loans & Advances 0 7.92 8.44 11.06 19.63
Other N/C Assets 0 0 0 0 0
Current Assets 0.08 930.7 1160.11 1622.53 2127.39
Total Assets 0.09 1475.4 1725.6 2220.57 2833.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations -0.01 228.3 421.07 470.94 564.93
Adjustment 0 -101.15 56.74 133.31 70.99
Changes in Assets & Liabilities -0.47 -93.26 -190.26 -107.58 99.84
Tax Paid 0 -23.54 -92.54 -108.56 -138.17
Operating Cash Flow -0.48 10.35 195.01 388.11 597.59
Investing Cash Flow 0 -8.83 -50.52 -68.73 -122.23
Financing Cash Flow 0.49 0.54 -136.55 -213.78 -78.8
Net Cash Flow 0.01 2.05 7.94 105.6 396.56

Corporate Actions

Investors Details

PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 82.84 82.85 82.85 82.85
glenmark pharmaceu... 82.84 82.84 82.84 82.84
glenn mario saldan... - 0.01 0.01 0.01
PARTICULARS Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 17.16 17.15 17.15 17.15
polar capital fund... 2.46 2.46 1.99 1.32

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ4FY22 30 Apr 2022
  • PresentationQ2FY22 16 Nov 2021
  • PresentationQ3FY22 11 Feb 2022

Glenmark Life Scienc Stock Price Analysis and Quick Research Report. Is Glenmark Life Scienc an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Life Scienc and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 597.585 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Life Scienc has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Life Scienc , the EPS growth was 4.7844190567299 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Life Scienc has OPM of 29.0154454520364 % which is a good sign for profitability.
     
  • ROE: Glenmark Life Scienc have a healthy ROE of 29.8708677999159 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Glenmark Life Scienc

X